Functional aberrant expression of CCR2 receptor on chronically activated NK cells in patients with TAP-2 deficiency

Blood

Volumn 106, Issue 10, 2005, Pages 3465-3473

  Hanna, Jacob ^b   Mussaffi, Huda ^b   Steuer, Guy ^b   Hanna, Suhair ^b   Deeb, Maher ^b   Blau, Hannah ^b   Arnon, Tal I ^b   Weizman, Noam ^b   Mandelboim, Ofer ^a  

^a HEBREW UNIVERSITY   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOATTRACTANT; CHEMOKINE RECEPTOR CCR2; INTERLEUKIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1;

ARTICLE; BLOOD ANALYSIS; CELL ACTIVATION; COMPARATIVE STUDY; FLOW CYTOMETRY; HIGH THROUGHPUT SCREENING; HUMAN; LUNG LAVAGE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 27744507838     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-03-0855     Document Type: Article

References (51)

1. de la Salle H, Hanau D, Fricker D, et al. Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science. 1994;265:237-241.
2. Zimmer J, Donato L, Hanau D, et al. Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). J Exp Med. 1998;187:117-122.
3. Vitale M, Zimmer J, Castriconi R, et al. Analysis of natural killer cells in TAP2-deficient patients: expression of functional triggering receptors and evidence for the existence of inhibitory receptor(s) that prevent lysis of normal autologous cells. Blood. 2002;99:1723-1729.
4. Markel G, Mussaffi H, Ling KL, et al. The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood. 2004;103:1770-1778.
5. Mandelboim O, Lieberman N, Lev M, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature. 2001;409:1055-1060.
6. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-274.
7. Moins-Teisserenc HT, Gadola SD, Cella M, et al. Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet. 1999;354:1598-1603.
8. Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity. 2002;16:1-4.
9. Annels NE, Da Costa CE, Prins FA, Willemze A, Hogendoorn PC, Egeler RM. Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. J Exp Med. 2003;197:1385-1390.
10. Markel G, Achdout H, Katz G, et al. Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients. Eur J Immunol. 2004;34:2138-2148.
11. Hanna J, Gonen-Gross T, Fitchett J, et al. Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest. 2004;114:1612-1623.
12. Mandelboim O, Reyburn HT, Vales-Gomez M, et al. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J Exp Med. 1996;184:913-922.
13. Hanna J, Fitchett J, Rowe T, et al. Proteomic analysis of human natural killer cells: insights on new potential NK immune functions. Mol Immunol. 2005;42:425-431.
14. Hanna J, Wald O, Goldman-Wohl D, et al. CXCL12 expression by invasive trophoblasts induces the specific migration of CD16- human natural killer cells. Blood. 2003;102:1569-1577.
15. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633-640.
16. Hanna J, Bechtel P, Zhai Y, Youssef F, McLachlan K, Mandelboim O. Novel insights on human NK cells' immunological modalities revealed by gene expression profiling. J Immunol. 2004;173:6547-6563.
17. dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation. Blood. 2004;105:3011-3018.
18. Campbell JJ, Qin S, Unutmaz D, et al. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol. 2001;166:6477-6482.
19. Sentman CL, Meadows SK, Wira CR, Eriksson M. Recruitment of uterine NK cells: induction of CXC chemokine ligands 10 and 11 in human endometrium by estradiol and progesterone. J Immunol. 2004;173:6760-6766.
20. Beider K, Nagler A, Wald O, et al. Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood. 2003;102:1951-1958.
21. Ferlazzo G, Thomas D, Lin SL, et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol. 2004;172:1455-1462.
22. Inngjerdingen M, Damaj B, Maghazachi AA. Expression and regulation of chemokine receptors in human natural killer cells. Blood. 2001;97:367-375.
23. Godiska R, Chantry D, Raport CJ, et al. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med. 1997;185:1595-1604.
24. Inngjerdingen M, Damaj B, Maghazachi AA. Human NK cells express CC chemokine receptors 4 and 8 and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine, and I-309. J Immunol. 2000;164:4048-4054.
25. Nieto M, Navarro F, Perez-Villar JJ, et al. Roles of chemokines and receptor polarization in NK-target cell interactions. J Immunol. 1998;161:3330-3339.
26. Polentarutti N, Allavena P, Bianchi G, et al. IL-2-regulated expression of the monocyte chemotactic protein-1 receptor (CCR2) in human NK cells: characterization of a predominant 3.4-kilobase transcript containing CCR2B and CCR2A sequences. J Immunol. 1997;158:2689-2694.
27. Allavena P, Bianchi G, Zhou D, et al. Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol. 1994;24:3233-3236.
28. Fraticelli P, Sironi M, Bianchi G, et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest. 2001;107:1173-1181.
29. Robertson MJ. Role of chemokines in the biology of natural killer cells. J Leukoc Biol. 2002;71:173-183.
30. Casilli F, Bianchini A, Gloaguen I, et al. Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2. Biochem Pharmacol. 2005;69:385-394.
31. Zimmermann N, Conkright JJ, Rothenberg ME. CC chemokine receptor-3 undergoes prolonged ligand-induced internalization. J Biol Chem. 1999;274:12611-12618.
32. Wald O, Pappo O, Safadi R, et al. Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol. 2004;34:1164-1174.
33. Martin-Fontecha A, Thomsen LL, Brett S, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004;5:1260-1265.
34. Yoneyama H, Narumi S, Zhang Y, et al. Pivotal role of dendritic cell-derived CXCL10 in the retention of T helper cell 1 lymphocytes in secondary lymph nodes. J Exp Med. 2002;195:1257-1266.
35. Patzwahl R, Meier V, Ramadori G, Mihm S. Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: detection by suppression-subtractive hybridization. J Virol. 2001;75:1332-1338.
36. Zimmer J, Donato L, Hanau D, et al. Inefficient protection of human TAP-deficient fibroblasts from autologous NK cell-mediated lysis by cytokines inducing HLA class I expression. Eur J Immunol. 1999;29:1286-1291.
37. Markel G, Wolf D, Hanna J, et al. Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Invest. 2002;110:943-953.
38. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003;422:198-207.
39. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121-127.
40. Quinones MP, Ahuja SK, Jimenez F, et al. Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J Clin Invest. 2004;113:856-866.
41. Hildebrandt GC, Duffner UA, Olkiewicz KM, et al. A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood. 2004;103:2417-2426.
42. Donnelly LE, Rogers DF. Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs. 2003;63:1973-1998.
43. Belperio JA, Keane MP, Burdick MD, et al. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest. 2001;108:547-556.
44. Okuma T, Terasaki Y, Kaikita K, et al. C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases. J Pathol. 2004;204:594-604.
45. Lu B, Rutledge BJ, Gu L, et al. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med. 1998;187:601-608.
46. Jinnouchi K, Terasaki Y, Fujiyama S, et al. Impaired hepatic granuloma formation in mice deficient in C-C chemokine receptor 2. J Pathol. 2003;200:406-416.
47. Scott HM, Flynn JL. Mycobacterium tuberculosis in chemokine receptor 2-deficient mice: influence of dose on disease progression. Infect Immun. 2002;70:5946-5954.
48. Peters W, Scott HM, Chambers HF, Flynn JL, Charo IF, Ernst JD. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2001;98:7958-7963.
49. Shang X, Qiu B, Frait KA, et al. Chemokine receptor 1 knockout abrogates natural killer cell recruitment and impairs type-1 cytokines in lymphoid tissue during pulmonary granuloma formation. Am J Pathol. 2000;157:2055-2063.
50. Merad M, Manz MG, Karsunky H, et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol. 2002;3:1135-1141.
51. Homey B, Alenius H, Muller A, et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med. 2002;8:157-165.